Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort

被引:15
|
作者
Dauby, Solene [1 ,2 ]
Dive, Dominique [1 ]
Lutteri, Laurence [4 ]
Andris, Cecile [3 ]
Hansen, Isabelle [1 ]
Maquet, Pierre [1 ,2 ]
Lommers, Emilie [1 ,2 ]
机构
[1] CHU Liege, Univ Hosp Liege, Clin Neuroimmunol Unit, Dept Neurol, Liege, Belgium
[2] Univ Liege, GIGA CRC Vivo Imaging, Liege, Belgium
[3] Univ Hosp Liege, Ophthalmol Dept, Clin Ophthalmol Unit, Liege, Belgium
[4] Univ Hosp Liege, Clin Chem Dept, Liege, Belgium
关键词
Neuromyelitis optica; MOG-associated disorders; AQP4-antibody NMO spectrum disorders; Optic neuritis; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OPTICA SPECTRUM DISORDERS; NEUROMYELITIS-OPTICA; CLINICAL PRESENTATION; TREATMENT RESPONSES; IGG; ANTIBODY; NEURITIS; MULTICENTER; AQUAPORIN-4;
D O I
10.1007/s13760-021-01712-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To emphasize physio-pathological, clinical and prognosis differences between conditions causing serious and sometimes very similar clinical manifestations: anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies related diseases, and seronegative NMOSD (neuromyelitis optica spectrum disorders). Based on Wingerchuk et al. (Neurology 85:177-189, 2015) criteria for NMOSD and on those more recently proposed by Jarius et al. (J Neuroinflammation 15:134, 2018) for MOGAD (MOG associated disorders), we retrospectively surveyed 10 AQP4-NMOSD, 8 MOGAD and 2 seronegative NMOSD, followed at the specialized neuroimmunology unit of the CHU Liege. Female predominance was only observed in AQP4 group. Age at onset was 37.8 and 27.7 years old for AQP4-NMOSD and MOGAD, respectively. In both groups, the first clinical event most often consisted of optic neuritis (ON), followed by isolated myelitis. Fifteen of our 20 patients encountered a relapsing course with 90% relapses in AQP4-NMOSD, 62.5% in MOGAD and 50% in the seronegative group, and a mean period between the first and second clinical event of 7.1 and 4.8 months for AQP4-NMOSD and MOGAD, respectively. In total, we counted 54 ON, with more ON per patient in MOGAD. MOG-associated ON mainly affected the anterior part of the optic nerve with a papilledema in 79.2% of cases. Despite a fairly good visual outcome after MOG-associated ON, retinal nerve fibre layer (RNFL) thickness decreased, suggesting a fragility of the optic nerve toward further attacks. As observed in larger cohorts, our MOGAD and AQP4-NMOSD cases differ by clinical and prognostic features. A better understanding of these diseases should encourage prompt biological screening and hasten proper diagnosis and treatment.
引用
收藏
页码:135 / 144
页数:10
相关论文
共 50 条
  • [21] Chinese sisters with NMOSD: one with AQP4 antibody seropositive and another with seronegative
    Xu, Wen
    Qiu, Wei
    Chen, Ying
    Dai, Yongqiang
    Lu, Zhengqi
    Hu, Xueqiang
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 693 - 694
  • [22] QOL associations with disability in Oxford AQP4 NMOSD cohort
    Eagle, Nina
    NEUROLOGY, 2021, 96 (15)
  • [23] Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America
    Rojas, Juan Ignacio
    Lopez, Pablo A.
    Criniti, Juan
    Pettinicchi, Juan Pablo
    Caride, Alejandro
    Diaz, Edgar Patricio Correa
    Granda, Ana Maria Toral
    Yepez, Maria Anggelica Ortiz
    Pachacama, Wilson Alfredo Gualotuna
    Andrade, Jefferson Santiago Piedra
    Marques, Vanessa Daccach
    Contreras, Elisa Bribiesca
    Figueroa, Enrique Gomez
    Rivera, Jose Flores
    Galleguillos, Lorna
    Navas, Carlos
    Neto, Herval R. Soares
    Gracia, Fernando
    Cristiano, Edgardo
    Patrucco, Liliana
    Becker, Jefferson
    Hamuy, Fernando
    Alonso, Ricardo
    Man, Federico
    Tkachuk, Veronica
    Nadur, Debora
    Lana-Peixoto, Marco
    de Castillo, Ibis Soto
    Contentti, Edgar Carnero
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71
  • [24] Different activation pattern of late complement pathway in the CSF between MOGAD and AQP4+NMOSD
    Kaneko, Kimihiko
    Kuroda, Hiroshi
    Ono, Hirohiko
    Matsumoto, Yuki
    Yamazaki, Naoya
    Yamamoto, Naoki
    Umezawa, Shu
    Namatame, Chihiro
    Takai, Yoshiki
    Takahashi, Toshiyuki
    Fujimori, Juichi
    Fujimori, Ichiro
    Harigaya, Yasuo
    Fujihara, Kazuo
    Misu, Tatsuro
    Aoki, Masashi
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP5 - NP5
  • [25] Investigating grey matter atrophy and its relationship with lesions in MS, MOGAD and AQP4+NMOSD
    Cortese, R.
    Battaglini, M.
    Prados, F.
    Jacob, A.
    Palace, J.
    Paul, F.
    Marignier, R.
    Rimkus, C. De Medeiros
    Filippi, M.
    Rocca, M.
    Rovira, A.
    Sastre-Garriga, J.
    Liu, Y.
    Gasperini, C.
    Tortorella, C.
    Amato, M.
    Groppa, S.
    Llufriu, S.
    Lukas, C.
    Sowa, P.
    Proebstel, A.
    Stankoff, B.
    Barkhof, F.
    Ciccarelli, O.
    De Stefano, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 101 - 101
  • [26] Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
    Siriratnam, Pakeeran
    Sanfilippo, Paul
    van der Walt, Anneke
    Sharmin, Sifat
    Foong, Yi Chao
    Yeh, Wei Zhen
    Zhu, Chao
    Khoury, Samia Joseph
    Csepany, Tunde
    Willekens, Barbara
    Etemadifar, Masoud
    Ozakbas, Serkan
    Nytrova, Petra
    Altintas, Ayse
    Al-Asmi, Abdullah
    Yamout, Bassem
    Laureys, Guy
    Patti, Francesco
    Simo, Magdolna
    Surcinelli, Andrea
    Foschi, Matteo
    McCombe, Pamela A.
    Alroughani, Raed
    Sanchez-Menoyo, Jose Luis
    Turkoglu, Recai
    Soysal, Aysun
    Lechner Scott, Jeanette
    Kalincik, Tomas
    Butzkueven, Helmut
    Jokubaitis, Vilija
    Huda, Saif
    Monif, Mastura
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024,
  • [27] Disease Characteristics of NMOSD and their Relationship with Disease Burden: Observations from a Large Single-center Cohort
    Khan, Erum
    Sriwastava, Shitiz
    Kagzi, Yosuf
    Amatya, Suban
    NEUROLOGY, 2024, 103 (07) : S104 - S104
  • [28] Comparative Analysis of Visual Characteristics and Neuro-axonal Damage across AQP4-IgG+ Neuromyelitis Optica, MOGAD, and Double Seronegative NMOSD patients presenting with Optic Neuritis
    Jain, Surbhi
    Mahadevan, Anita
    Bhat, Maya
    Kumar, Vinay
    Netravathi, M.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 951 - 952
  • [29] C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
    Pache, Florence
    Ringelstein, Marius
    Aktas, Orhan
    Kleiter, Ingo
    Jarius, Sven
    Siebert, Nadja
    Bellmann-Strobl, Judith
    Paul, Friedemann
    Ruprecht, Klemens
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 360
  • [30] Therapeutic strategies of rituximab in NMOSD and MOGAD patients: multicenter cohort study in Latin America
    Contentti, E. Carnero
    Lopez, P.
    Criniti, J.
    Pettinicchi, J.
    Caride, A.
    Correa-Diaz, E. P.
    Granda, A. M. Toral
    Yepez, M. A. Ortiz
    Pachacama, W. A. Gualotuna
    Andrade, J. S. Piedra
    Marques, V. Daccach
    Contreras, E. Bribiesca
    Gomez-Figueroa, E.
    Flores, J.
    Galleguillos, L.
    Navas, C.
    Soares Neto, H.
    Crisitiano, E.
    Patrucco, L.
    Becker, J.
    Hamuy, F.
    Alonso, R.
    Silva, B.
    Man, F.
    Tkachuk, V.
    Nadur, D.
    Lana-Peixoto, M.
    De Castillo, I. Soto
    Rojas, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 753 - 754